Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Intellectual PropertyPatentsThe Intellectual Property StrategistColumns & Departments

IP News

By Sarah Brand and Jeff Ginsberg
June 30, 2025

Federal Circuit: District Court Did Not Err In Declining to Find Infringement By Moderna’s Activities Involving COVID-19 Vaccine


On June 4, 2025, a Federal Circuit panel consisting of Judges Taranto, Chen, and Hughes issued a unanimous opinion, authored by Judge Taranto, in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc., Case No. 2023-2357. The panel affirmed the U.S. District Court for the District of Delaware’s decision that appellee’s activities involving its mRNA-based COVID-19 vaccine SPIKEVAX® did not infringe appellant’s U.S. Patent Nos. 11,246,933 (’933 patent) or 11,382,979 (’979 patent). Slip Op. at 2–3.

Alnylam Pharmaceuticals, Inc., (Alnylam) owns the ’933 and ’979 patents. Id. at 2. The ’979 patent is the child of the ’933 patent. Id. Both patents are directed to biodegradable lipids and their use for the delivery of active agents, such as nucleic acids. Id. at 3. Specifically, the ’933 and ’979 patents disclosed a cationic lipid with at least a branched alkyl terminal hydrophobic chain in at least one biodegradable hydrophobic tail. Id. at 5. In March 2022, Alnylam sued Defendants Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc. (collectively Moderna) in the U.S. District Court for the District of Delaware, alleging that Moderna infringed the ’933 patent through activities involving the SM-102 lipid in SPIKEVAX®. Id. at 6. In July 2022, after the ’979 patent issued, Alnylam sued Moderna in the same forum for alleged infringement of the ’979 patent through activities involving SPIKEVAX®. Id. The two pending actions were consolidated. Id.

This premium content is locked for The Intellectual Property Strategist subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

Compliance Officers: Recent Regulatory Guidance and Enforcement Actions and Mitigating the Risk of Personal Liability Image

This article explores legal developments over the past year that may impact compliance officer personal liability.